Journal: Nature communications

Article Title: Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids

doi: 10.1038/ncomms2886

Figure Lengend Snippet: a , Confocal images (top) and FACS quantitative analysis (bottom) of PKH26-labeled GNVs taken up by non-hematopoietic cells (A549, GL26, 4T1, SW620 and CT26) and primary splenic lymphocytes (T and B cells). b , Temperature (T), c , Time (n=3) and d , concentration dependence on the efficiency of GNVs uptake (n=3). e , Potential pathways utilized by GNVs to enter A549 cells. f , Stability of cationic DOTAP:DOPE liposomes (top) and GNVs (bottom) at 37°C in the presence of 10% fetal bovine serum. *** p <0.001 (Student’s t-test). Data (a-e) are the mean±s.e.m. of at least five independent experiments.

Article Snippet: In our second set of experiments, six-week-old female NOD-SCID mice (Jackson Lab) were injected subcutaneously with the human colon cancer SW620 cell line (5.0×10 6 cells/mouse in 50 μl of PBS).

Techniques: Labeling, Concentration Assay, Liposomes

Journal: Nature communications

Article Title: Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids

doi: 10.1038/ncomms2886

Figure Lengend Snippet: a , C57BL/6J mice were implanted with GL26-Luc cells, GNVs were loaded with Stat3 inhibitor JSI-124 and then intranasally administrated to mice. The mice were imaged on post-injection days as indicated in a . A representative photograph showing the brain tumor signals of a mouse from each group ( n = 5) ( a , left). The growth potential of injected GL26-Luc cells was determined by dividing photon emissions of mice treated with PBS by the photon emissions of mice treated with GNVs, JSI-124, or GNVs-JSI-124 ( a , right, top). The results are based on two independent experiments with data pooled for mice in each experiment ( n = 5) and presented as the mean ± s.e.m.; * p < 0.05. Surviving percent of GNVs-JSI-124-treated mice was compared to control mice. One representative experiment of 2 independent experiments is shown ( n = 5) (* p <0.05) ( a , right, bottom). b , Tumor cells were injected s.c. into BALB/c mice (CT26, 1×10 6 /mouse, left, top) or NOD-SCID mice (SW620, 5×10 6 /mouse, left, bottom). After tumor cells were injected, mice were treated with DiR dye labeled agents as listed in via i.v. injection every three days for a total of ten injections. Tumor volume was measured every 3 days. On day 30 after tumor cells were injected, tumors were removed and imaged with a Kodak Image station. Representative images of tumors from each group ( n =5) are shown ( b , middle). Right panels show the mean intensity of the DiR fluorescent signals of tumor (Mean net intensity = Sum Intensity/Area, n=5). The results are presented as the mean ± s.e.m. ** p <0.01 and *** p <0.001 (One-way and Two-way analysis of variance, ANOVA). c , CT26-Luc tumor cell bearing mice were i.v. injected with luciferase siRNA (50 pmol/mouse in 200 nmol GNVs), luciferase siRNA carried by GNVs, or folic acid and luciferase siRNA co-delivered by GNVs every 3 days for a total of 5 injections. Representative images (left, n=5) and mean intensity of the luciferase activity of CT26-Luc tumor (right, mean net intensity = Sum Intensity/Area, n=5) before and after treatments are presented. * p <0.05.

Article Snippet: In our second set of experiments, six-week-old female NOD-SCID mice (Jackson Lab) were injected subcutaneously with the human colon cancer SW620 cell line (5.0×10 6 cells/mouse in 50 μl of PBS).

Techniques: Injection, Control, Labeling, Luciferase, Activity Assay